Surface Oncology, Inc. (NASDAQ:SURF) Expected to Post Earnings of -$0.36 Per Share

Brokerages predict that Surface Oncology, Inc. (NASDAQ:SURF) will post earnings of ($0.36) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Surface Oncology’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.20). Surface Oncology posted earnings of ($0.39) per share during the same quarter last year, which suggests a positive year over year growth rate of 7.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 9th.

According to Zacks, analysts expect that Surface Oncology will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($0.96). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.67) to ($1.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Surface Oncology.

Surface Oncology (NASDAQ:SURF) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.13). The company had revenue of $0.52 million during the quarter.

A number of research analysts have recently commented on SURF shares. BTIG Research restated a “buy” rating and issued a $17.00 target price on shares of Surface Oncology in a research note on Sunday, September 19th. Jonestrading reissued a “buy” rating and set a $18.00 price target on shares of Surface Oncology in a report on Friday, June 4th. Finally, Zacks Investment Research lowered Surface Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, August 7th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.80.

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Surface Oncology by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 77,029 shares of the company’s stock valued at $601,000 after purchasing an additional 1,401 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new stake in shares of Surface Oncology during the 2nd quarter valued at $26,000. UBS Group AG lifted its holdings in shares of Surface Oncology by 52.9% during the 1st quarter. UBS Group AG now owns 11,466 shares of the company’s stock valued at $90,000 after purchasing an additional 3,966 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Surface Oncology by 4,700.0% during the 1st quarter. Captrust Financial Advisors now owns 4,800 shares of the company’s stock valued at $37,000 after purchasing an additional 4,700 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Surface Oncology by 16.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 34,834 shares of the company’s stock valued at $260,000 after purchasing an additional 4,870 shares during the last quarter. Hedge funds and other institutional investors own 49.77% of the company’s stock.

Shares of SURF stock traded up $0.17 during trading hours on Wednesday, reaching $7.57. The company’s stock had a trading volume of 3,386 shares, compared to its average volume of 1,318,957. The stock has a market capitalization of $344.07 million, a P/E ratio of 20.56 and a beta of 1.83. Surface Oncology has a one year low of $4.95 and a one year high of $14.40. The firm’s fifty day simple moving average is $6.19 and its 200 day simple moving average is $7.22. The company has a current ratio of 9.13, a quick ratio of 9.13 and a debt-to-equity ratio of 0.07.

About Surface Oncology

Surface Oncology, Inc operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells.

Featured Article: How is a management fee different from a performance fee?

Get a free copy of the Zacks research report on Surface Oncology (SURF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.